Search
ATAI Life Sciences NV
ATAIAdd to Watchlist
7.180USD
0.0000.00%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.66BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of ATAI Life Sciences NV is 8.43, ranking 128 out of 385 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 16.00 and a low of 7.00.
Analyst Rating
Based on
15
analysts
Hold
Current Rating
10.683
Target Price
+48.79%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
ATAI Life Sciences NV
ATAI
15
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ATAI Life Sciences NV's expected revenue for the next quarter?
ATAI Life Sciences NV's expected revenue is 10.00K.
What is ATAI Life Sciences NV's price target?
Analysts forecast that ATAI Life Sciences NV's price target is USD 12.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 7.00.
How have ATAI Life Sciences NVATAI's recent earnings per share performed?
The market expectation was USD -0.08, while ATAI Life Sciences NVATAI's earnings per share (EPS) for the previous quarter was USD -1.73. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for ATAI Life Sciences NV?
Based on the ratings of ATAI Life Sciences NV's stock from 15 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.